genedx was founded in 2000 by two scientists from the national institutes of health (nih) to address the needs of patients and clinicians in diagnosing rare inherited disorders. currently, genedx offers testing for more than 400 rare mendelian disorders, and gene panels for inherited cardiac disorders, inherited cancer syndromes, neurological disorders, and mitochondrial disorders. in addition, genedx also offers whole exome sequencing and whole genome chromosomal microarray testing. our highly trained and experienced physicians, geneticists, and genetic counselors work as a team to bring gene discoveries to clinical medicine for use in direct patient care. for more information, please visit our website at www.genedx.com
Company profile
Ticker
BRLI, BRLIR, BRLIU, BRLIW
Exchange
CEO
Chuan Wei Chen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Brilliant Acquisition Corp
SEC CIK
BRLI stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Nukkleus Appoints C. Derek Campbell to Board of Directors, Bolstering its Growing Footprint in Emerging Markets
26 Jan 24
8-K
Nukkleus Signs MOU to Substantially Increase Holdings in Jacobi Asset Management
17 Jan 24
8-K
Other Events
11 Jan 24
8-K
Nukkleus Inc. Closes Merger with Brilliant Acquisition Corporation
2 Jan 24
NT 10-K
Notice of late annual filing
2 Jan 24
25-NSE
Exchange delisting
22 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Dec 23
425
Business combination disclosure
1 Dec 23
Latest ownership filings
SC 13G
GOLDMAN SACHS GROUP INC
13 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
7 Feb 23
SC 13G/A
Karpus Management, Inc.
10 Nov 22
SC 13G/A
Feis Lawrence
8 Aug 22
4
Yebo Shen
21 Apr 22
4
Brian Ferrier
20 Apr 22
3
Brian Ferrier
11 Mar 22
3
Yebo Shen
11 Mar 22
SC 13G
Karpus Management, Inc.
14 Feb 22
SC 13G
MIZUHO FINANCIAL GROUP INC
14 Feb 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.61 mm | 4.61 mm | 4.61 mm | 4.61 mm | 4.61 mm | 4.61 mm |
Cash burn (monthly) | (no burn) | 2.22 mm | 38.89 k | 35.54 k | 40.33 k | 31.88 k |
Cash used (since last report) | n/a | 14.79 mm | 259.47 k | 237.11 k | 269.06 k | 212.68 k |
Cash remaining | n/a | -10.18 mm | 4.35 mm | 4.37 mm | 4.34 mm | 4.40 mm |
Runway (months of cash) | n/a | -4.6 | 111.8 | 123.0 | 107.6 | 137.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 5.26 bn |
Total shares | 3.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MFG Mizuho Financial | 459.12 k | $0.00 |
Newtyn Management | 457.41 k | $95.60 mm |
Mangrove Partners | 417.90 k | $4.86 bn |
Owl Creek Asset Management | 399.02 k | $83.40 mm |
Yakira Capital Management | 301.50 k | $42.29 mm |
Sea Otter Advisors | 269.61 k | $56.35 mm |
Walleye Capital | 254.54 k | $34.94 mm |
HRT Financial | 191.26 k | $25.00 k |
Feis Lawrence Michael | 178.93 k | $1.88 mm |
Walleye Trading | 143.19 k | $19.66 mm |